ProQR Therapeutics (PRQR) Total Non-Current Liabilities (2013 - 2026)

ProQR Therapeutics has reported Total Non-Current Liabilities for 14 years, with the latest figure at $30.9 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 24.79% year-over-year to $30.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.9 million (down 24.79% YoY) and the FY2025 annual result came in at $36.0 million, down 16.77% from the prior year.
• Total Non-Current Liabilities fell to $30.9 million in Q1 2026 per PRQR's latest filing, from $36.0 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $85.3 million in Q4 2022 and troughed at $30.9 million in Q1 2026.
• A 5-year average of $48.0 million and a median of $42.4 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities increased 8.51% in 2022, then sank 35.43% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $85.3 million in 2022, then decreased by 21.47% to $67.0 million in 2023, then plunged by 35.43% to $43.3 million in 2024, then slipped by 16.77% to $36.0 million in 2025, then decreased by 14.26% to $30.9 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $30.9 million, $36.0 million, and $39.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.